Overview
The actively managed equity fund focused on bottom-up active stock selection within Europe.
The fund aims to invests in selected European companies, that trade below their long term fair values based on fundamental analysis.
Exposure to the European market is ensured via diversification across various countries and sectors.
Actively managed fund based on a concentrated portfolio of attractively valued stocks.
The portfolio manager is not tied to the benchmark in terms of investment selection or weight.
Benefits
Easy access to European equity markets
The portfolio may deviate sharply from the reference index in order to increase outperformance potential.
The fund managers can also tap into the knowledge and experience of a network of equity analysts around the globe.
Investors benefit from the fact that 麻豆社 is one of the few asset managers with a truly global investment platform.
Risks
Features
| Product category |
麻豆社 Equity Funds 麻豆社 Value Funds |
| Product domicile |
Luxembourg
|
| Portfolio management |
麻豆社 Asset Management (UK) Ltd., London
|
| Fund management |
麻豆社 Asset Management (Europe) S.A., Luxembourg
|
| Custodian bank |
麻豆社 Europe SE, Luxembourg Branch
|
| Representative for products established under foreign law |
麻豆社 Asset Management (UK) Limited
|
| Day of inception |
21 October 2015
|
| Currency of account |
EUR
|
| Close of financial year |
30 September
|
| SFDR Classification |
Art.8
|
| Issue / redemption |
daily
|
| Distribution |
Reinvestment
|
| Maturity |
Open end
|
| Ongoing costs p.a. |
1.02% p.a.
|
| Management fee |
0.76% p.a.
|
| Total expense ratio (TER) |
1.02% p.a.
|
| Swing pricing |
yes
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
MSCI Europe (net div. reinv.)
|
| ISIN |
LU0421769745
|
| Bloomberg Ticker |
麻豆社KQAE LX
|
Performance and Prices
Percentage growth
as of 18 June 2026| EUR(%) | |
| YTD | |
| 1M | |
| 3M | 7.33 |
| 6M | 15.14 |
| 1Y | 28.90 |
| 2Y | 42.11 |
| 3Y | 65.23 |
| 5Y | |
| ø p.a.5Y | 15.30 |
| EUR(%) | |
| Q1 2025 to Q1 2026 | 21.08 |
| Q1 2024 to Q1 2025 | 12.91 |
| Q1 2023 to Q1 2024 | 14.76 |
| Q1 2022 to Q1 2023 | 8.86 |
| Q1 2021 to Q1 2022 | 14.51 |
Current data
| Net asset value | 18.06.2026 | EUR 276.86 |
| High - last 12 months | 16.06.2026 | EUR 278.69 |
| Low - last 12 months | 25.06.2025 | EUR 211.53 |
| Assets of the unit class in mn | 17.06.2026 | EUR 56.25 |
| Total product assets in mn | 17.06.2026 | EUR 672.90 |
|
Date
|
2 years
|
5 years
|
|
| Total risk reference index / benchmark | 31.05.2026 | 10.94% | 12.48% |
| Sharpe Ratio | 31.05.2026 | 1.19 | 0.95 |
| Risk Free Rate | 31.05.2026 | 2.60% | 1.98% |
Structures
By the 10 largest equity positions (in %, as of 29 May 2026)
|
|
|
| BNP Paribas SA | 3.93 |
| AstraZeneca PLC | 3.84 |
| Nestle SA | 3.79 |
| Roche Holding AG | 3.61 |
| Novartis AG | 3.29 |
| Banco Bilbao Vizcaya Argentaria SA | 3.24 |
| ASML Holding NV | 3.19 |
| Infineon Technologies AG | 3.19 |
| Diageo PLC | 2.82 |
| TotalEnergies SE | 2.73 |
Fees
Distributions
Sales Authorisations
Literature
|
Document type
|
Document Language
|
| Prospectus |
|
| Country supplement |
|
| Key Investor Information (KIID) |
|
| Past performance |
|
| Previous performance scenario |
|
| ESG Disclosure |
|
| SFDR Pre-Contractual Annex |
|
|
Document type
|
Document Language
|
| Annual report |
|
| Semi-annual report |
|